



COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

DAPSONE (2)

SUMMARY REPORT

1. Dapsone had previously been scientifically assessed according to the requirements of Council Regulation (EEC) 2377/90. The measures taken according to this assessment had been published in Commission Regulation (EEC) 675/92¹.
2. A provisional MRL of 25 µg/kg for the parent drug was established for the tissues muscle, liver, kidney and fat and for milk, applicable to all food-producing species. A time period terminating on 1 January 1994 was applied to the provisional MRL. Further information on teratogenic and reproductive effects was required.
3. However, no further data were provided at the time of expiry of the provisional MRL. Therefore, the time period of the provisional MRL terminates on 1 January 1994 and the compound will be entered into Annex IV.

¹ OJ No L73, 19.3.92, p. 8